MMMT
MCID: CRC021
MIFTS: 62

Carcinosarcoma (MMMT)

Categories: Bone diseases, Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Carcinosarcoma

MalaCards integrated aliases for Carcinosarcoma:

Name: Carcinosarcoma 12 52 54 43 15
Malignant Mixed Mullerian Tumor 12 52
Mixed Tumor, Mesodermal 43 17
Mixed Tumor, Mullerian 52 43
Mmmt 12 52
Malignant Mixed Mesodermal Tumor 12
Malignant Mixed Müllerian Tumor 74
Mixed Mesodermal Tumor 12
Mesodermal Mixed Tumor 12
Mullerian Mixed Tumor 12
Mixed Müllerian Tumor 74
Mixed Mullerian Tumor 52
Mixed Tumor Mullerian 54

Classifications:



External Ids:

Disease Ontology 12 DOID:4236
SNOMED-CT 67 63264007 84427001
UMLS 71 C0007140 C0206627 C1334603

Summaries for Carcinosarcoma

NIH Rare Diseases : 52 A malignant mixed mullerian tumor (MMMT) , also called a carcinosarcoma , is a type of cancer that contains two types of cancer cells - carcinoma and sarcoma cells. These tumors usually develop in tissues of the female genital tract and are associated with a poor outcome. The majority of these tumors arise in the uterus, though they can also occur in the ovaries, fallopian tubes, and cervix. Very rarely, MMMTs can develop in the female peritoneum (lining of the abdominal wall).

MalaCards based summary : Carcinosarcoma, also known as malignant mixed mullerian tumor, is related to ovarian carcinosarcoma and primary peritoneal carcinoma. An important gene associated with Carcinosarcoma is VIM (Vimentin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Paclitaxel and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include uterus, lung and ovary, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A mixed cell type cancer that has material basis in carcinomatous (epithelial tissue) and sarcomatous (connective tissue) components.

Wikipedia : 74 A malignant mixed Müllerian tumor, also known as malignant mixed mesodermal tumor (MMMT) is a cancer... more...

Related Diseases for Carcinosarcoma

Diseases related to Carcinosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 844)
# Related Disease Score Top Affiliating Genes
1 ovarian carcinosarcoma 34.8 TP53 PPP2R1A PIK3CA ERBB2
2 primary peritoneal carcinoma 33.1 TP53 PGR ERBB2
3 rare tumor 31.8 KIT DES ACTC1
4 adenosarcoma 31.5 VIM TP53 PGR MME MB KIT
5 uterine carcinosarcoma 31.4 VIM TP53 S100A1 PTEN PPP2R1A POLE
6 spindle cell sarcoma 31.2 VIM MUC1 KRT7 DES ACTC1
7 fibrosarcoma 31.1 VIM TP53 KIT DES ACTC1
8 thyroid carcinoma 31.0 PTEN PIK3CA HRAS
9 bilateral breast cancer 30.9 PTEN PIK3CA PGR ERBB2
10 neuroendocrine carcinoma 30.9 PTEN MUC1 KRT7 KIT
11 anal squamous cell carcinoma 30.9 TP53 PIK3CA FBXW7
12 benign teratoma 30.9 TP53 MUC1 KRT7
13 spindle cell carcinoma 30.8 VIM PGR MUC1 KRT7 HRAS DES
14 clear cell adenocarcinoma 30.8 TP53 PIK3CA KRT7
15 botryoid rhabdomyosarcoma 30.8 MB DES ACTC1
16 thymoma, familial 30.8 KIT HRAS
17 fibrous histiocytoma 30.8 VIM TP53 KIT DES ACTC1
18 mesenchymal cell neoplasm 30.7 TP53 MME KIT
19 bizarre leiomyoma 30.7 TP53 PGR ACTC1
20 large cell neuroendocrine carcinoma 30.7 KRT7 KIT ERBB2
21 embryonal sarcoma 30.7 VIM TP53 KIT DES CTNNB1
22 adenoma 30.7 TP53 PIK3CA MUC1 KRT7 KRAS CTNNB1
23 ovarian serous carcinoma 30.7 TP53 KRAS ERBB2
24 krukenberg carcinoma 30.7 MUC1 KRT7
25 pulmonary blastoma 30.6 TP53 KRAS DES ACTC1
26 endodermal sinus tumor 30.6 VIM KRT7 KIT
27 testicular germ cell tumor 30.6 TP53 PTEN KIT HRAS
28 adrenocortical carcinoma, hereditary 30.6 TP53 PIK3CA CTNNB1
29 transitional cell carcinoma 30.6 TP53 PTEN PIK3CA KRT7 HRAS ERBB2
30 eccrine porocarcinoma 30.6 VIM MUC1 KRT7
31 breast metaplastic carcinoma 30.5 PGR MME ERBB2
32 cystic teratoma 30.5 TP53 PTEN KRT7 KRAS KIT
33 mature teratoma 30.5 TP53 KRT7 KRAS KIT ERBB2
34 mucinous cystadenocarcinoma 30.5 VIM MUC1 KRT7 ACTC1
35 papillary serous adenocarcinoma 30.5 TP53 PGR KRT7 KRAS
36 small cell carcinoma 30.4 TP53 PTEN MUC1 KRT7 KRAS KIT
37 ameloblastoma 30.4 TP53 KRAS CTNNB1
38 lung benign neoplasm 30.4 TP53 KRT7 KRAS HRAS
39 basal cell carcinoma 30.4 TP53 PTEN MME KRT7 KIT CTNNB1
40 vulvar intraepithelial neoplasia 30.4 TP53 CTNNB1
41 medulloepithelioma 30.4 VIM MUC1 KRT7 DES
42 spindle cell thymoma 30.4 MUC1 DES
43 malignant fibrous histiocytoma 30.4 VIM TP53 MUC1 MB KIT DES
44 skin carcinoma 30.4 TP53 KRT7 HRAS CTNNB1
45 adrenal cortical carcinoma 30.4 VIM TP53 MUC1 CTNNB1 ACTC1
46 liposarcoma 30.3 VIM TP53 PTEN PIK3CA MB DES
47 breast mucinous carcinoma 30.3 PGR KRT7 ERBB2
48 breast fibroadenoma 30.3 TP53 PGR MME ERBB2
49 leiomyosarcoma 30.3 VIM TP53 S100A1 PGR MUC1 MB
50 brooke-spiegler syndrome 30.3 VIM TP53 KRT7

Graphical network of the top 20 diseases related to Carcinosarcoma:



Diseases related to Carcinosarcoma

Symptoms & Phenotypes for Carcinosarcoma

GenomeRNAi Phenotypes related to Carcinosarcoma according to GeneCards Suite gene sharing:

26 (show all 17)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.3 HRAS KRAS MUC1 PIK3CA
2 Decreased viability GR00055-A-2 10.3 HRAS KRAS MUC1 PIK3CA
3 Decreased viability GR00055-A-3 10.3 KRAS
4 Decreased viability GR00106-A-0 10.3 KRAS
5 Decreased viability GR00221-A-1 10.3 HRAS KRAS PIK3CA
6 Decreased viability GR00221-A-2 10.3 HRAS KRAS PIK3CA
7 Decreased viability GR00221-A-3 10.3 HRAS
8 Decreased viability GR00221-A-4 10.3 PIK3CA
9 Decreased viability GR00249-S 10.3 MUC1
10 Decreased viability GR00301-A 10.3 KRAS
11 Decreased viability GR00381-A-1 10.3 KRAS
12 Decreased viability GR00402-S-2 10.3 PIK3CA
13 Decreased cell migration GR00055-A-1 9.5 VIM
14 Decreased cell migration GR00055-A-3 9.5 HRAS PIK3CA
15 Increased cell death in HCT116 cells GR00103-A-0 9.46 CTNNB1 FBXW7 PIK3CA PPP2R1A
16 Reduced mammosphere formation GR00396-S 9.23 DES HRAS KRAS KRT7 POLE PPP2R1A
17 Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading GR00210-A 8.65 CTNNB1

MGI Mouse Phenotypes related to Carcinosarcoma:

45 (show all 18)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.46 ACTC1 CTNNB1 DES ERBB2 FBXW7 KIT
2 homeostasis/metabolism MP:0005376 10.45 ACTC1 CTNNB1 DES ERBB2 FBXW7 HRAS
3 cardiovascular system MP:0005385 10.44 ACTC1 CTNNB1 DES ERBB2 FBXW7 HRAS
4 behavior/neurological MP:0005386 10.42 CTNNB1 DES ERBB2 HRAS KIT KRAS
5 mortality/aging MP:0010768 10.31 ACTC1 CTNNB1 DES ERBB2 FBXW7 HRAS
6 embryo MP:0005380 10.26 CTNNB1 ERBB2 FBXW7 KIT KRAS MB
7 integument MP:0010771 10.23 CTNNB1 ERBB2 FBXW7 HRAS KIT KRAS
8 immune system MP:0005387 10.22 CTNNB1 FBXW7 KIT KRAS MME PGR
9 endocrine/exocrine gland MP:0005379 10.21 CTNNB1 ERBB2 FBXW7 HRAS KIT KRAS
10 muscle MP:0005369 10.18 ACTC1 CTNNB1 DES ERBB2 KIT KRAS
11 digestive/alimentary MP:0005381 10.14 CTNNB1 ERBB2 FBXW7 HRAS KIT KRAS
12 neoplasm MP:0002006 10.1 CTNNB1 ERBB2 FBXW7 HRAS KIT KRAS
13 craniofacial MP:0005382 10.09 CTNNB1 ERBB2 FBXW7 HRAS KIT KRAS
14 nervous system MP:0003631 10.03 ACTC1 CTNNB1 ERBB2 FBXW7 HRAS KIT
15 limbs/digits/tail MP:0005371 9.98 CTNNB1 ERBB2 KIT KRAS PGR PTEN
16 normal MP:0002873 9.73 ACTC1 CTNNB1 ERBB2 FBXW7 HRAS KIT
17 no phenotypic analysis MP:0003012 9.7 CTNNB1 HRAS KIT KRAS PGR PIK3CA
18 respiratory system MP:0005388 9.36 CTNNB1 ERBB2 FBXW7 HRAS KIT KRAS

Drugs & Therapeutics for Carcinosarcoma

Drugs for Carcinosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 124)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
2
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
3
Bevacizumab Approved, Investigational Phase 3 216974-75-3
4
Lenograstim Approved, Investigational Phase 3 135968-09-1
5
Mesna Approved, Investigational Phase 3 3375-50-6 598
6
Ifosfamide Approved Phase 3 3778-73-2 3690
7
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
8
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
9
Gemcitabine Approved Phase 2, Phase 3 95058-81-4 60750
10
Doxorubicin Approved, Investigational Phase 2, Phase 3 23214-92-8 31703
11
Niraparib Approved, Investigational Phase 2, Phase 3 1038915-60-4 24958200
12
Histamine Approved, Investigational Phase 3 51-45-6 774
13
Cyproheptadine Approved Phase 3 129-03-3 2913
14 Albumin-Bound Paclitaxel Phase 3
15 Tubulin Modulators Phase 3
16 Antimitotic Agents Phase 3
17 Anti-Bacterial Agents Phase 3
18 Antibiotics, Antitubercular Phase 3
19 Antineoplastic Agents, Immunological Phase 3
20 Angiogenesis Inhibitors Phase 3
21 Alkylating Agents Phase 3
22
Isophosphamide mustard Phase 3 0
23 Poly(ADP-ribose) Polymerase Inhibitors Phase 2, Phase 3
24
Liposomal doxorubicin Phase 2, Phase 3 31703
25 Neurotransmitter Agents Phase 3
26 Histamine Antagonists Phase 3
27 Anti-Allergic Agents Phase 3
28
Histamine Phosphate Phase 3 51-74-1 65513
29 Histamine H1 Antagonists Phase 3
30 Dermatologic Agents Phase 3
31 Gastrointestinal Agents Phase 3
32
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
33
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
34
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
35
Trabectedin Approved, Investigational Phase 2 114899-77-3 108150
36
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
37
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
38
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
39
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
40
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
41
Olaparib Approved Phase 1, Phase 2 763113-22-0 23725625
42
Metformin Approved Phase 2 657-24-9 14219 4091
43
Doxycycline Approved, Investigational, Vet_approved Phase 2 564-25-0 54671203
44
Fludarabine Approved Phase 2 21679-14-1, 75607-67-9 30751
45
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
46
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704 32326
47
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
48
Durvalumab Approved, Investigational Phase 2 1428935-60-7
49
Pemetrexed Approved, Investigational Phase 2 137281-23-3, 150399-23-8 60843 446556
50
Etoposide Approved Phase 2 33419-42-0 36462

Interventional clinical trials:

(show top 50) (show all 103)
# Name Status NCT ID Phase Drugs
1 A Phase III Trial of Ifosfamide (NSC #109274) Versus Ifosfamide Plus Paclitaxel (NSC #125973) in Patients With Advanced, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus Completed NCT00003128 Phase 3 ifosfamide;paclitaxel
2 A Phase III Randomized Study of Accelerated Hyperfractionated Whole Abdominal Radiotherapy (AHWAR) Versus Combination Ifosfamide-Mesna With Cisplatin in Optimally Debulked Stage I, II, III, or IV Carcinosarcoma (CS) of The Uterus Completed NCT00002546 Phase 3 cisplatin;ifosfamide
3 Phase III Randomized Study of Adjuvant Pelvic Radiotherapy Versus Observation Alone in Patients With Completely Resected, Stage I or II, High-Grade Uterine Sarcoma Completed NCT00002459 Phase 3
4 RANDOMISED TRIAL OF ADJUVANT CHEMOTHERAPY WITH HIGH-DOSE DOXORUBICIN, IFOSFAMIDE AND LENOGRASTIM IN HIGH GRADE SOFT TISSUE SARCOMA Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
5 ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
6 Short Course Adjuvant Vaginal Cuff Brachytherapy (VCB) in Early Endometrial Cancer Compared to Standard of Care (SAVE) Recruiting NCT03422198 Phase 3
7 A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary Active, not recruiting NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
8 A Multicentric Randomized Phase II/III Evaluating TSR-042 (Anti-PD-1 mAb) in Combination With Niraparib (Parpi) Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy Not yet recruiting NCT03651206 Phase 2, Phase 3 Niraparib;Chemotherapy Drugs
9 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
10 Phase II Trial On Trabectedin In The Treatment Of Advanced Uterine And Ovarian Carcinosarcoma (CS)_MITO 26 Unknown status NCT02993705 Phase 2 Trabectedin
11 Phase II Evaluation of Temodal (Temozolomide, Schering) in Previously Treated Advanced Sarcomas Unknown status NCT00003718 Phase 2 temozolomide
12 A Randomised Feasibility Study of Extended Chemotherapy With Neoadjuvant Carboplatin, Then Surgery Followed by Adjuvant Paclitaxel and Gemcitabine Verses Neoadjuvant Gemcitabine and Carboplatin, Then Surgery, Followed by Adjuvant Paclitaxel Unknown status NCT00838656 Phase 2 carboplatin;gemcitabine hydrochloride;paclitaxel
13 A Phase II Multicenter Trial of Paclitaxel and Carboplatin in Women With Advanced (IIIb, IIIc, IVa and IVb) or Recurrent (All Stages) Malignant Mixed Mullerian Tumors (MMMT) of the Uterus Completed NCT00502203 Phase 2 Carboplatin;Paclitaxel
14 A Phase II Study of VEGF-Trap in Recurrent or Metastatic Gynecologic Soft-Tissue Sarcomas Completed NCT00390234 Phase 2 ziv-aflibercept
15 A Phase II Study of Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus Completed NCT00476086 Phase 2 Gemcitabine;Oxaliplatin
16 A Phase II Study of BAY 43-9006 in Advanced/Recurrent Uterine Carcinoma/Carcinosarcoma Completed NCT00238121 Phase 2 sorafenib tosylate
17 A Phase II Evaluation of Ixabepilone (NSC #710428) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT01168232 Phase 2 Ixabepilone
18 A Phase II Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00687687 Phase 2 paclitaxel;carboplatin;BSI-201 (Iniparib)
19 A Phase II Evaluation of Pazopanib (NSC # 737754) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT01247571 Phase 2 Pazopanib Hydrochloride
20 A Phase II Evaluation of Gemcitabine (NSC #613327) and Docetaxel (NSC # 628503) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00114218 Phase 2 Gemcitabine Hydrochloride;Docetaxel
21 Phase II Study of Paclitaxel (TAXOL), Intraperitoneal Cisplatin and IV Avastin Followed by Avastin Consolidation for Advanced Ovarian and Peritoneal Carcinoma or Fallopian Tube Cancer Completed NCT00511992 Phase 2 Avastin;Paclitaxel;Cisplatin
22 A Phase 2 Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma Completed NCT00478426 Phase 2 Sunitinib Malate
23 A Phase II Evaluation of Thalidomide (NSC #66847) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00025506 Phase 2 Thalidomide
24 A Phase II Evaluation of Gleevec(TM) (NCI-Supplied Agent: STI571 [Imatinib Mesylate], NSC# 716051) in the Treatment of Recurrent or Persistent Carcinosarcoma of the Uterus Completed NCT00075400 Phase 2 imatinib mesylate
25 A Phase 2 Trial of Temsirolimus and Bevacizumab in Patients With Endometrial, Ovarian, Hepatocellular Carcinoma, Carcinoid or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
26 A Pilot Phase II Trial of Adjuvant Radiation Therapy "Sandwiched" Between Ifosfamide in Patients With Mixed Mesodermal Tumors Completed NCT00231842 Phase 2 Ifosfamide;Cisplatin
27 Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors Completed NCT00815945 Phase 2 PegLiposomal Doxorubicin;Carboplatin
28 A Randomized Phase II Trial of Avastin (A) or Avastin and Erlotinib (AE) as First Line Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Newly Diagnosed Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors Completed NCT00520013 Phase 2 bevacizumab;erlotinib;paclitaxel;carboplatin
29 A Phase II Evaluation of Paclitaxel (Taxol, NSC # 673089) and Carboplatin (Paraplatin, NSC #241240) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma Completed NCT00112489 Phase 2 carboplatin;paclitaxel
30 Phase II Study of Thalidomide (NSC #66847) in Patients With Sarcomas of Gynecologic Origin Completed NCT00006005 Phase 2 thalidomide
31 A Phase 2 Study of AZD0530 in Recurrent or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2 saracatinib
32 Phase II Study of Doxil and Paclitaxel in Patients With Endometrial, Tubal, and Sarcomas of Gynecologic Origin Completed NCT00003334 Phase 2 paclitaxel;pegylated liposomal doxorubicin hydrochloride
33 Evaluation of Doxil in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus Completed NCT00005643 Phase 2 pegylated liposomal doxorubicin hydrochloride
34 Phase II Study on ET-743 in Advanced Soft Tissue Sarcomas of the Adult Completed NCT00003939 Phase 2 trabectedin
35 Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI) Completed NCT00526149 Phase 2 BI 2536
36 Dose Finding and Phase II Study of STI 571 in Advanced Soft Tissue Sarcoma Completed NCT00006357 Phase 1, Phase 2 imatinib mesylate
37 Phase I/II Trial, Dose Finding Combination Chemotherapy With PegLiposomal Doxorubicin (PLD) And Carboplatin In Patients With Gynecologic Tumors Completed NCT00032162 Phase 1, Phase 2 carboplatin;pegylated liposomal doxorubicin hydrochloride
38 A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas Completed NCT00245102 Phase 2 sorafenib tosylate
39 A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent®, SU11248) in Non-GIST Sarcomas Completed NCT00474994 Phase 2 sunitinib malate
40 Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
41 An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors Recruiting NCT03601897 Phase 1, Phase 2 rebastinib;Paclitaxel
42 A Phase II Trial of IDO-Inhibitor, BMS-986205, and PD-1 Inhibitor, Nivolumab, in Patients With Recurrent or Persistent Endometrial Cancer or Endometrial Carcinosarcomas (CA017-056) Recruiting NCT04106414 Phase 2 Nivolumab;BMS- 986205
43 A Phase 2 Study of the Wee1 Inhibitor AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma Recruiting NCT03668340 Phase 2 AZD1775
44 An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma Recruiting NCT03694262 Phase 2 Rucaparib;Bevacizumab;Atezolizumab
45 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Recruiting NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
46 DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors Recruiting NCT02834013 Phase 2
47 A Phase II, Signal-Seeking Trial of the Clinical Benefit Rate Associated With Pamiparib in Subjects With Germline or Somatic BRCA1/2 High Grade Serous Ovarian Cancer or Carcinosarcoma Who Have Progressed on P-gp Substrate Chemotherapy or PARPi With the Presence of an ABCB1 Fusion and the Absence of a BRCA1/2 Reversion Recruiting NCT03933761 Phase 2 Pamiparib
48 An International Multi-centre Randomised Phase II Study to Assess the Efficacy of TAK228 in Combination With Intravenous Weekly Paclitaxel Compared With Weekly Paclitaxel Alone in Women With Advanced/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Recruiting NCT03648489 Phase 2 Paclitaxel;TAK228
49 A Phase I/II Study of Olaparib With Entinostat in the Treatment of Recurrent, Platinum-Refractory or Resistant, Homologous Recombination Repair Proficient Ovarian, Primary Peritoneal, and Fallopian Tube Cancers Recruiting NCT03924245 Phase 1, Phase 2 Entinostat;Olaparib
50 A Phase II Study of Metformin in Combination With Doxycycline in Patients With Localized Breast, and Uterine, and Cervical Cancer Recruiting NCT02874430 Phase 2 Metformin Hydrochloride;Doxycycline

Search NIH Clinical Center for Carcinosarcoma

Cochrane evidence based reviews: carcinosarcoma

Genetic Tests for Carcinosarcoma

Anatomical Context for Carcinosarcoma

MalaCards organs/tissues related to Carcinosarcoma:

40
Uterus, Lung, Ovary, Breast, Liver, Prostate, Cervix

Publications for Carcinosarcoma

Articles related to Carcinosarcoma:

(show top 50) (show all 3875)
# Title Authors PMID Year
1
Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus. 54 61
20189232 2010
2
Intraductal carcinosarcoma with a heterologous mesenchymal component originating in intraductal papillary-mucinous carcinoma (IPMC) of the pancreas with both carcinoma and osteosarcoma cells arising from IPMC cells. 61 54
20203229 2010
3
Tissue microarray analysis of hormonal signaling pathways in uterine carcinosarcoma. 61 54
19200930 2009
4
Carcinosarcoma of the gallbladder producing alpha-fetoprotein and manifesting as leukocytosis with elevated serum granulocyte colony-stimulating factor: report of a case. 54 61
19280285 2009
5
Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. 61 54
16648864 2006
6
Carcinosarcoma of the liver producing granulocyte-colony stimulating factor. 61 54
16792552 2006
7
Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours. 54 61
16140564 2006
8
EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. 61 54
16157366 2006
9
Role of Rho, Rac, and Rho-kinase in phosphorylation of myosin light chain, development of polarity, and spontaneous migration of Walker 256 carcinosarcoma cells. 61 54
15950966 2005
10
Imatinib mesylate (gleevec)--targeted kinases are expressed in uterine sarcomas. 61 54
15894930 2005
11
Effusion cytodiagnosis of carcinosarcoma derived from the female genital tract: immunohistochemical features of MMP-7 and Ki-67 and immunofluorescence double staining analyses of eight cases. 61 54
15863125 2005
12
HER-2/neu oncogene in uterine carcinosarcoma on tamoxifen therapy. 54 61
15901136 2005
13
ERBB-2 gene overexpression and amplification in uterine sarcomas. 54 61
15581967 2004
14
Aberrant nuclear/cytoplasmic localization and gene mutation of beta-catenin in classic pulmonary blastoma: beta-catenin immunostaining is useful for distinguishing between classic pulmonary blastoma and a blastomatoid variant of carcinosarcoma. 61 54
15223963 2004
15
Pulmonary carcinomas with pleomorphic, sarcomatoid, or sarcomatous elements: a clinicopathologic and immunohistochemical study of 75 cases. 54 61
12604887 2003
16
Expression of CD10 in malignant müllerian mixed tumors and adenosarcomas: an immunohistochemical study. 54 61
12218209 2002
17
Well-differentiated endometrial adenocarcinomas and poorly differentiated mixed mullerian tumors have altered ER and PR isoform expression. 54 61
11687977 2001
18
Co-expression of tenascin-C and vimentin in human breast cancer cells indicates phenotypic transdifferentiation during tumour progression: correlation with histopathological parameters, hormone receptors, and oncoproteins. 61 54
11180164 2001
19
Testicular Sertoli cell tumor with a heterologous sarcomatous component: immunohistochemical assessment of Sertoli cell differentiation. 61 54
9786352 1998
20
Uterine angiosarcomas: a morphologic and immunohistochemical study of four cases. 61 54
9500227 1998
21
Carcinosarcoma of the prostate. A case report and a possible evidence on the role of hormonal therapy. 61 54
9313326 1997
22
Immunohistochemical study of the histogenesis of esophageal carcinosarcoma. 54 61
1283991 1992
23
Effects of staurosporine, K 252a and other structurally related protein kinase inhibitors on shape and locomotion of Walker carcinosarcoma cells. 61 54
1457347 1992
24
Thymic carcinosarcoma associated with a spindle cell thymoma: an immunohistochemical study. 61 54
1398523 1992
25
Utility of immunohistochemistry in distinguishing ovarian sertoli-stromal cell tumors from carcinosarcomas. 61 54
1612579 1992
26
Comparative investigation of c-erbB2/neu expression in head and neck tumors and mammary cancer. 54 61
1672262 1991
27
Carcinosarcoma of the prostate in combination with adenocarcinoma of the prostate and adenocarcinoma of the seminal vesicles. A case report with immunocytochemical analysis and review of the literature. 61 54
2201434 1990
28
An immunohistological comparison of primary lung carcinosarcoma and sarcoma. 54 61
1696005 1990
29
PD-L1 pathway as a novel target in carcinosarcoma of the kidney and renal pelvis. 61
32489894 2020
30
Carcinosarcoma of the parotid gland with mucoepidermoid carcinoma component. 61
32550959 2020
31
Impact of different adjuvant treatment approaches on survival in stage III endometrial cancer: A population-based study. 61
32454416 2020
32
Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. 61
31714586 2020
33
Synchronous Well-differentiated Endometrioid Adenocarcinoma and Leiomyosarcoma of the Uterus With Pulmonary Metastasis in a 50-Yr-Old Woman: A Case Report and Review of Literature. 61
31157684 2020
34
The in vivo modulatory effects of Cornus mas extract on photodynamic therapy in experimental tumors. 61
31926344 2020
35
Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86). 61
31992589 2020
36
The current clinical approach to newly diagnosed uterine cancer. 61
32531179 2020
37
Mismatch Repair Deficiency in Uterine Carcinosarcoma: A Multi-institution Retrospective Review. 61
31934920 2020
38
Cutaneous Adnexal Carcinosarcoma: Immunohistochemical and Molecular Evidence of Epithelial Mesenchymal Transition. 61
32564423 2020
39
Odontogenic Carcinosarcoma: Clinicopathologic Features of 2 Cases. 61
31786969 2020
40
Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma. 61
32526764 2020
41
Carcinosarcoma of the Stomach. 61
32519247 2020
42
Managing the unexpected: Carcinosarcoma of the kidney parenchyma A case with the longest follow-up. 61
32567506 2020
43
Primary cutaneous carcinosarcoma: clinical, histological, and immunohistochemical analysis of eight cases. 61
32530054 2020
44
Trichoblastic Carcinosarcoma Arising From the Vagina: A Case Report With Comprehensive Immunophenotypic Analysis. 61
31747847 2020
45
Palliative electrochemotherapy in primary or recurrent vulvar cancer. 61
32371425 2020
46
S100A4/non-muscle myosin II signaling regulates epithelial-mesenchymal transition and stemness in uterine carcinosarcoma. 61
31857700 2020
47
A comprehensive analysis of IDO1 expression with tumour-infiltrating immune cells and mutation burden in gynaecologic and breast cancers. 61
32227579 2020
48
Salivary Carcinosarcoma: An Extremely Rare and Highly Aggressive Malignancy. 61
31291005 2020
49
Primary sarcoma of the cervix: an analysis of patient and tumor characteristics, treatment patterns, and outcomes. 61
31912680 2020
50
Chemotherapy alone may have equivalent survival as compared to suboptimal surgery in advanced endometrial cancer patients. 61
32099891 2020

Variations for Carcinosarcoma

Cosmic variations for Carcinosarcoma:

9 (show top 50) (show all 522)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87905773 TP53 ovary,NS,carcinoma,adenocarcinoma c.542G>A p.R181H 17:7675070-7675070 6
2 COSM87899223 TP53 ovary,NS,carcinoma,adenocarcinoma c.578A>T p.H193L 17:7674953-7674953 6
3 COSM87898818 TP53 ovary,NS,carcinoma,adenocarcinoma c.916C>T p.R306* 17:7673704-7673704 6
4 COSM87905366 TP53 ovary,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 17:7675136-7675136 6
5 COSM87901171 TP53 ovary,NS,carcinoma,adenocarcinoma c.395A>G p.K132R 17:7675217-7675217 6
6 COSM145422024 TNFAIP3 ovary,NS,carcinoma,adenocarcinoma c.940G>A p.V314I 6:137877210-137877210 6
7 COSM91381505 SMAD4 ovary,NS,carcinoma,adenocarcinoma c.1051G>C p.D351H 18:51065518-51065518 6
8 COSM88349172 SMAD2 ovary,NS,carcinoma,adenocarcinoma c.785-1G>C p.? 18:47848688-47848688 6
9 COSM92365507 RET ovary,NS,carcinoma,adenocarcinoma c.3253A>G p.T1085A 10:43128177-43128177 6
10 COSM90833519 PTCH1 ovary,NS,carcinoma,adenocarcinoma c.3074G>A p.R1025H 9:95458107-95458107 6
11 COSM87152527 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1034A>T p.N345I 3:179203764-179203764 6
12 COSM87132544 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1636C>A p.Q546K 3:179218306-179218306 6
13 COSM87145727 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.3012G>T p.M1004I 3:179234169-179234169 6
14 COSM87139234 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.2725T>C p.F909L 3:179230062-179230062 6
15 COSM97107326 NRAS ovary,NS,carcinoma,adenocarcinoma c.181C>A p.Q61K 1:114713909-114713909 6
16 COSM97107379 NRAS ovary,NS,carcinoma,adenocarcinoma c.35G>A p.G12D 1:114716126-114716126 6
17 COSM87804005 KRAS ovary,NS,carcinoma,adenocarcinoma c.35G>A p.G12D 12:25245350-25245350 6
18 COSM87804055 KRAS ovary,NS,carcinoma,adenocarcinoma c.35G>T p.G12V 12:25245350-25245350 6
19 COSM88586417 ERBB2 ovary,NS,carcinoma,adenocarcinoma c.2524G>A p.V842I 17:39725079-39725079 6
20 COSM86804346 EGFR ovary,NS,carcinoma,adenocarcinoma c.2099A>G p.N700S 7:55173958-55173958 6
21 COSM86804352 EGFR ovary,NS,carcinoma,adenocarcinoma c.2123A>G p.K708R 7:55173982-55173982 6
22 COSM86808602 EGFR ovary,NS,carcinoma,adenocarcinoma c.2597A>G p.E866G 7:55191846-55191846 6
23 COSM86751503 EGFR ovary,NS,carcinoma,adenocarcinoma c.2494C>T p.R832C 7:55191743-55191743 6
24 COSM86769580 EGFR ovary,NS,carcinoma,adenocarcinoma c.2173A>G p.T725A 7:55174032-55174032 6
25 COSM86757992 EGFR ovary,NS,carcinoma,adenocarcinoma c.2108T>C p.L703P 7:55173967-55173967 6
26 COSM86757673 EGFR ovary,NS,carcinoma,adenocarcinoma c.2174C>T p.T725M 7:55174033-55174033 6
27 COSM86757974 EGFR ovary,NS,carcinoma,adenocarcinoma c.2159C>T p.S720F 7:55174018-55174018 6
28 COSM86770841 EGFR ovary,NS,carcinoma,adenocarcinoma c.2481C>T p.Y827= 7:55191730-55191730 6
29 COSM86748127 EGFR ovary,NS,carcinoma,adenocarcinoma c.2573T>G p.L858R 7:55191822-55191822 6
30 COSM86751403 EGFR ovary,NS,carcinoma,adenocarcinoma c.2161G>A p.G721S 7:55174020-55174020 6
31 COSM86757983 EGFR ovary,NS,carcinoma,adenocarcinoma c.2232C>A p.I744= 7:55174769-55174769 6
32 COSM86761167 EGFR ovary,NS,carcinoma,adenocarcinoma c.2506C>A p.R836S 7:55191755-55191755 6
33 COSM86751510 EGFR ovary,NS,carcinoma,adenocarcinoma c.2604A>T p.E868D 7:55191853-55191853 6
34 COSM86780270 EGFR ovary,NS,carcinoma,adenocarcinoma c.2112G>A p.L704= 7:55173971-55173971 6
35 COSM86767926 EGFR ovary,NS,carcinoma,adenocarcinoma c.2122A>G p.K708E 7:55173981-55173981 6
36 COSM86755734 EGFR ovary,NS,carcinoma,adenocarcinoma c.2559C>T p.I853= 7:55191808-55191808 6
37 COSM86770885 EGFR ovary,NS,carcinoma,adenocarcinoma c.2165C>T p.A722V 7:55174024-55174024 6
38 COSM86805588 EGFR ovary,NS,carcinoma,adenocarcinoma c.2556G>T p.K852N 7:55191805-55191805 6
39 COSM88138689 ATM ovary,NS,carcinoma,adenocarcinoma c.1810C>T p.P604S 11:108252824-108252824 6
40 COSM97820944 AR ovary,NS,carcinoma,adenocarcinoma c.2179C>T p.R727C 23:67717483-67717483 6
41 COSM133536287 AKT1 ovary,NS,carcinoma,adenocarcinoma c.235C>A p.Q79K 14:104776711-104776711 6
42 COSM148939078 ovary,NS,carcinoma,adenocarcinoma c.2725T>C p.F909L 3:179230062-179230062 6
43 COSM111761369 ovary,NS,carcinoma,adenocarcinoma c.395A>G p.K132R 17:7675217-7675217 6
44 COSM142841902 ovary,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 17:7675136-7675136 6
45 COSM122736483 ovary,NS,carcinoma,adenocarcinoma c.-2A>G p.? 17:7675217-7675217 6
46 COSM147950776 ovary,NS,carcinoma,adenocarcinoma c.*163A>G p.? 7:55174032-55174032 6
47 COSM111980548 ovary,NS,carcinoma,adenocarcinoma c.2462A>G p.E821G 7:55191846-55191846 6
48 COSM145024458 ovary,NS,carcinoma,adenocarcinoma c.425G>A p.R142H 17:7675070-7675070 6
49 COSM121879352 ovary,NS,carcinoma,adenocarcinoma c.-2A>G p.? 17:7675217-7675217 6
50 COSM139858573 ovary,NS,carcinoma,adenocarcinoma c.695-1G>C p.? 18:47848688-47848688 6

Expression for Carcinosarcoma

Search GEO for disease gene expression data for Carcinosarcoma.

Pathways for Carcinosarcoma

Pathways related to Carcinosarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 75)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.04 VIM TP53 S100A1 PTEN PPP2R1A PIK3CA
2
Show member pathways
13.85 VIM TP53 PTEN PPP2R1A MUC1 KRAS
3
Show member pathways
13.76 PPP2R1A PIK3CA MUC1 KRAS KIT HRAS
4
Show member pathways
13.53 PPP2R1A PIK3CA KRT7 KRAS KIT HRAS
5
Show member pathways
13.49 TP53 PTEN PPP2R1A PIK3CA KRAS KIT
6
Show member pathways
13.4 VIM TP53 PPP2R1A PIK3CA MUC1 KRAS
7
Show member pathways
13.31 VIM PPP2R1A KRAS KIT HRAS ERBB2
8
Show member pathways
13.15 TP53 PTEN PPP2R1A PIK3CA KIT ERBB2
9
Show member pathways
13.09 TP53 PPP2R1A PIK3CA KRAS HRAS CTNNB1
10
Show member pathways
12.93 PTEN PIK3CA KRAS HRAS ERBB2 CTNNB1
11
Show member pathways
12.89 TP53 PTEN PPP2R1A PIK3CA KRAS KIT
12
Show member pathways
12.86 TP53 PTEN PIK3CA KRAS KIT HRAS
13 12.82 TP53 PTEN PIK3CA KRAS KIT HRAS
14 12.8 TP53 KRAS KIT HRAS ERBB2
15
Show member pathways
12.77 PIK3CA KRAS KIT HRAS CTNNB1
16
Show member pathways
12.75 TP53 PTEN PIK3CA KRAS HRAS ERBB2
17
Show member pathways
12.73 TP53 PTEN PIK3CA KRAS HRAS ERBB2
18
Show member pathways
12.67 TP53 PTEN PIK3CA KRAS HRAS ERBB2
19
Show member pathways
12.64 VIM PTEN PIK3CA KRAS HRAS
20
Show member pathways
12.64 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
21
Show member pathways
12.61 TP53 PTEN PPP2R1A PIK3CA KRAS KIT
22
Show member pathways
12.58 TP53 PTEN PIK3CA PGR KRAS KIT
23 12.56 VIM MUC1 KRT7 DES ACTC1
24
Show member pathways
12.56 TP53 PTEN PIK3CA KRAS HRAS ERBB2
25
Show member pathways
12.52 PTEN PIK3CA KRAS HRAS ERBB2
26 12.51 VIM TP53 PTEN PIK3CA KRAS HRAS
27
Show member pathways
12.5 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
28
Show member pathways
12.44 PTEN PIK3CA KRAS HRAS
29
Show member pathways
12.44 PIK3CA KRAS KIT HRAS
30
Show member pathways
12.44 PIK3CA KRAS HRAS CTNNB1
31
Show member pathways
12.44 PIK3CA KRAS KIT HRAS ERBB2 CTNNB1
32
Show member pathways
12.44 TP53 PTEN PIK3CA MUC1 KRAS HRAS
33
Show member pathways
12.43 TP53 PTEN PIK3CA HRAS
34
Show member pathways
12.4 PPP2R1A PIK3CA PGR KRAS
35 12.4 TP53 PTEN PIK3CA KRAS HRAS
36
Show member pathways
12.36 TP53 PTEN PIK3CA HRAS ERBB2 CTNNB1
37
Show member pathways
12.35 PIK3CA KRAS HRAS ERBB2
38 12.33 TP53 PIK3CA KRAS HRAS
39 12.31 TP53 PIK3CA KRAS HRAS ERBB2 CTNNB1
40
Show member pathways
12.3 PPP2R1A PIK3CA KRAS HRAS
41
Show member pathways
12.29 TP53 PTEN PIK3CA KRAS HRAS ERBB2
42
Show member pathways
12.29 PIK3CA MUC1 KRAS HRAS ERBB2 CTNNB1
43 12.22 PTEN KRAS HRAS ERBB2
44
Show member pathways
12.21 TP53 PIK3CA KRAS HRAS
45
Show member pathways
12.21 PTEN PIK3CA KIT HRAS
46 12.21 TP53 PTEN PIK3CA KRAS HRAS
47
Show member pathways
12.19 PTEN PIK3CA KRAS HRAS ERBB2
48 12.18 TP53 PTEN KRAS CTNNB1
49
Show member pathways
12.17 TP53 PIK3CA KRAS HRAS
50 12.15 PIK3CA KRAS HRAS CTNNB1

GO Terms for Carcinosarcoma

Cellular components related to Carcinosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.13 VIM PTEN PPP2R1A POLE PIK3CA MUC1
2 cytosol GO:0005829 9.83 VIM TP53 PTEN PPP2R1A PIK3CA PGR
3 extracellular exosome GO:0070062 9.81 VIM PPP2R1A MUC1 MME MB KRT7
4 focal adhesion GO:0005925 9.65 VIM MME KRAS CTNNB1 ACTC1
5 cytoplasm GO:0005737 9.58 VIM TP53 S100A1 PTEN PPP2R1A PIK3CA
6 fascia adherens GO:0005916 9.37 DES CTNNB1

Biological processes related to Carcinosarcoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.88 PTEN KRAS KIT HRAS ERBB2 CTNNB1
2 negative regulation of gene expression GO:0010629 9.83 TP53 PGR HRAS FBXW7 CTNNB1
3 Ras protein signal transduction GO:0007265 9.7 TP53 KRAS HRAS
4 positive regulation of MAPK cascade GO:0043410 9.67 KIT HRAS ERBB2 CTNNB1
5 muscle filament sliding GO:0030049 9.65 VIM DES ACTC1
6 heart development GO:0007507 9.65 TP53 PTEN MB ERBB2 CTNNB1
7 phosphatidylinositol 3-kinase signaling GO:0014065 9.63 PTEN PIK3CA ERBB2
8 positive regulation of transcription from RNA polymerase II promoter in response to stress GO:0036003 9.51 TP53 MUC1
9 vasculature development GO:0001944 9.5 PIK3CA FBXW7 CTNNB1
10 response to isolation stress GO:0035900 9.49 KRAS HRAS
11 positive regulation of MAP kinase activity GO:0043406 9.46 KRAS KIT HRAS ERBB2
12 cytokine-mediated signaling pathway GO:0019221 9.43 VIM TP53 PIK3CA MUC1 KRAS KIT
13 positive regulation of gene expression GO:0010628 9.28 VIM TP53 PTEN KRAS KIT HRAS

Molecular functions related to Carcinosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.91 VIM TP53 S100A1 PTEN PPP2R1A POLE
2 identical protein binding GO:0042802 9.23 VIM TP53 S100A1 PTEN PGR FBXW7

Sources for Carcinosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....